Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

: SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper - XML Representation

Active as of 2023-11-26

Raw xml | Download



<Library xmlns="http://hl7.org/fhir">
  <id value="179632"/>
  <meta>
    <versionId value="2"/>
    <lastUpdated value="2023-11-26T22:51:21.545Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><h2>Participants</h2><table class="grid"><tr><td>Author</td><td>Brian S. Alper</td></tr></table><h2>Related Artifacts</h2><table class="grid"><tr><td>derived-from</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr></table><h2>Contents</h2></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="cds"/>
  </extension>
  <url value="https://fevir.net/resources/Library/179632"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179632"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <version value="1.0.0-ballot"/>
  <title
         value="SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper"/>
  <status value="active"/>
  <type>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/library-type"/>
      <code value="asset-collection"/>
      <display value="Asset Collection"/>
    </coding>
  </type>
  <subjectReference>🔗 
    <reference value="Group/179619"/>
    <type value="Group"/>
    <display
             value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
  </subjectReference>
  <date value="2023-11-26T18:15:27.442Z"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description value="11 excluded studies"/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="SystematicReviewExcludedStudies"/>
        <display value="SystematicReviewExcludedStudies"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Brian S. Alper"/>
  </author>
  <relatedArtifact>
    <type value="derived-from"/>
    <resourceReference>🔗 
      <reference value="Citation/179613"/>
      <type value="Citation"/>
      <display
               value="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Different comparison (ADT versus ADT plus estramustine)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179628"/>
      <type value="Citation"/>
      <display
               value="14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text
            value="Different comparison (ADT versus ADT plus chemotherapy without docetaxel)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179631"/>
      <type value="Citation"/>
      <display
               value="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179627"/>
      <type value="Citation"/>
      <display
               value="19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179626"/>
      <type value="Citation"/>
      <display
               value="22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179625"/>
      <type value="Citation"/>
      <display
               value="22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Nonrandomized"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179629"/>
      <type value="Citation"/>
      <display
               value="23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Neoadjuvant treatment"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179624"/>
      <type value="Citation"/>
      <display
               value="24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Nonrandomized"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179622"/>
      <type value="Citation"/>
      <display
               value="26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="High-risk localized prostate cancer"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179621"/>
      <type value="Citation"/>
      <display
               value="26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text
            value="Locally advanced or metastatic (without metastatic subgroup analysis)"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179630"/>
      <type value="Citation"/>
      <display
               value="26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."/>
    </resourceReference>
  </relatedArtifact>
  <relatedArtifact>
    <type value="contains"/>
    <classifier>
      <text value="Nonrandomized"/>
    </classifier>
    <resourceReference>🔗 
      <reference value="Citation/179623"/>
      <type value="Citation"/>
      <display
               value="23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."/>
    </resourceReference>
  </relatedArtifact>
</Library>